Immutep partners with Dr. Reddy's for oncology drug commercialization

Immutep Limited and Dr. Reddy's Laboratories Ltd. announced a strategic collaboration for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China. Under the agreement, Immutep will receive an upfront payment of $20 million.

Immutep is also eligible for potential regulatory development and commercial milestone payments totaling up to $349.5 million, in addition to double-digit royalties on commercial sales. Immutep retains global manufacturing rights for efti and will supply the product to Dr. Reddy's for the licensed markets, while maintaining full rights to the product in key pharmaceutical markets including North America, Europe, and Japan.

Efti is a first-in-class novel immunotherapy currently in a registrational Phase III trial (TACTI-004, KEYNOTE-F91) for first-line therapy of advanced non-small cell lung cancer, and is also being investigated for other indications such as head & neck cancer, breast cancer, and soft tissue sarcoma.